ArticleOncoimmunology
The ratio of CD8
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 55 citations in OpenAlex.
- Prediction of histological grading in ductal carcinomaFrontiers in oncology · 2026Article
- Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights.Discover oncology · 2025Review
- Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series.Annals of translational medicine · 2024Article
- Impact of microbiota on breast cancer hormone therapy.Cell stress · 2023Article
- Delineating spatial cell-cell interactions in the solid tumour microenvironment through the lens of highly multiplexed imaging.Frontiers in immunology · 2023Review
- Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis.American journal of physiology. Cell physiology · 2022Review
- Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer.Cancer discovery · 2022Article
- Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.British journal of cancer · 2022Article
- Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ.NPJ breast cancer · 2022Article
- Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ.Breast (Edinburgh, Scotland) · 2022Article
- Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2.Biomedicines · 2022Review
- Article
- The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer.Discover oncology · 2022Article
- Obesity modulates the immune macroenvironment associated with breast cancer development.PloS one · 2022Article
- Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases.Oncoimmunology · 2022Article
- Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.British journal of cancer · 2021Article
- Beneficial autoimmunity improves cancer prognosis.Nature reviews. Clinical oncology · 2021Review
- Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells.Biology · 2021Article
- Difference in the distribution of tumor-infiltrating CD8+ T cells and FOXP3+ T cells between micronodular thymoma with lymphoid stroma and micronodular thymic carcinoma with lymphoid stroma.Pathology international · 2021Article
- Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.Oncoimmunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 3 countries.
Michaela SemeraroGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Julien AdamDepartment of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France; Module de Développement en Pathologie Expérimentale-INSERM U981, Gustave-Roussy Cancer Campus, Villejuif, France.
Gautier StollGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Emilie LouvetModule de Développement en Pathologie Expérimentale-INSERM U981, Gustave-Roussy Cancer Campus , Villejuif, France.
Kariman ChabaGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Vichnou Poirier-ColameFaculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France; Department of Immuno-Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Allan SauvatGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Laura SenovillaGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Erika VacchelliGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Norma BloyGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Faculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France.
Juliette HumeauGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Faculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France.
Aitziber BuqueGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Oliver KeppGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Laurence ZitvogelFaculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France; Department of Immuno-Oncology, Gustave Roussy Cancer Campus, Villejuif, France; INSERM, U1015, Villejuif, France.
Fabrice AndréINSERM, U981 "Identification of molecular predictors and new targets for cancer treatment", Villejuif, France; Department of Medical Oncology and Breast Cancer Group, Gustave Roussy Cancer Campus, Villejuif, France.
Marie-Christine MathieuDepartment of Medical Biology and Pathology, Gustave Roussy Cancer Campus , Villejuif, France.
Suzette DelalogeDepartment of Medical Oncology and Breast Cancer Group, Gustave Roussy Cancer Campus , Villejuif, France.
Guido KroemerGustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
Inserm · FRDélégation Paris 5 · FRInstitut Gustave Roussy · FRCentre de Recherche des Cordeliers · FRSorbonne Université · FRSorbonne Paris Cité · FRUniversité Paris Cité · FRUniversité Paris-Saclay · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a series of 248 tumor samples obtained from image-guided biopsies from patients diagnosed with ductal carcinoma
Indexed as
Cytotoxic T cellshyperploidyimmunogenic cell deathimmunosuppressive regulatory T cellsintraductal carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.